MRC cashes in on basic research success

一月 30, 1998

The Medical Research Council this week became the first of the UK research councils to launch a venture capital fund to help commercialise basic research. The UK Medical Ventures Fund, which has so far raised Pounds 30 million, will establish and invest in new and recentlyformed companies to exploit biotechnologies resulting mostly from MRC fundamental research.

It will have exclusive rights for six months to review and select biotechnology for commercialisation. The fund, which is seeking up to Pounds 40 million, will be led by Stephen Reeders, a physician with research and investment experience. Investors so far include a small group of international pharmaceutical companies and UK financial institutions, with the largest single commitment, Pounds 11 million, received from investment capital group 3i.

请先注册再继续

为何要注册?

  • 注册是免费的,而且十分便捷
  • 注册成功后,您每月可免费阅读3篇文章
  • 订阅我们的邮件
注册
Please 登录 or 注册 to read this article.
ADVERTISEMENT